Taysha Gene Therapies downgraded at Morgan Stanley on management uncertainty

As previously reported, Morgan Stanley analyst Michael Ulz downgraded Taysha Gene Therapies to Equal Weight from Overweight with a price target of $3, down from $23. The firm’s prior rating was based on the potential of the CNS targeted gene therapy pipeline, but the recent CEO and CMO resignations ahead of key events in the first half of this year create near-term uncertainty that prompts them to move to the sidelines.